Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 4Not yet recruiting 2Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 7Thyroid Neoplasms 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Extensive Stage 1Proteinuria 1Platinum-resistant Ovarian Cancer (PROC) 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Melanoma 1Limited Stage Small Cell Lung Cancer 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

toripalimab 6130-nm albumin-bound paclitaxel 6Cisplatin 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Neoadjuvant Therapy 2Esophagectomy 2Capecitabine 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1fluzoparib 1Watchful Waiting 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Paclitaxel 1Observation 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × anlotinib × Clear all
NCT07128693 2025-08-19

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
60 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06426797 2024-05-23

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Peking University People's Hospital

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡